Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.48 |
| ▸ | EDNRA | P25101 | 6/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.38 |
| ▸ | BCL2 | P10415 | 3/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702525 | 0.88 | PTGES (0.40) | PTGESMCL1BCL2KMT2AEPHX2 | |
| SCHEMBL4699422 | 0.85 | PTGES (0.49) | PTGESEDNRARXRARXRBMCL1 | |
| SCHEMBL4917265 | 0.83 | PPARG (0.46) | PTGES | |
| SCHEMBL3578280 | 0.81 | PTGES (0.53) | PTGESEDNRARXRARXRBMCL1 | |
| SCHEMBL4699431 | 0.78 | PTGES (0.58) | PTGESNR1H4 | |
| SCHEMBL4702217 | 0.78 | PTGES (0.43) | PTGESEDNRARXRARXRBMCL1 | |
| SCHEMBL4025672 | 0.77 | PTGES (0.55) | PTGESEDNRARXRARXRBMCL1 | |
| SCHEMBL4027503 | 0.76 | PTGES (0.71) | PTGESEDNRAEDNRB | |
| SCHEMBL3013326 | 0.75 | PTGES (0.62) | PTGES | |
| SCHEMBL4701667 | 0.75 | PTGES (0.46) | PTGESMCL1BCL2MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778633-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | PTGES 4/4885EDNRA 71/4885RXRA 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.